| Literature DB >> 30871010 |
Vinícius de S Pinto1, Janay S C Araújo2, Rai C Silva3, Glauber V da Costa4, Jorddy N Cruz5, Moysés F De A Neto6, Joaquín M Campos7, Cleydson B R Santos8, Franco H A Leite9,10, Manoelito C S Junior11.
Abstract
Tuberculosis (TB) is an infection caused by Mycobacterium tuberculosis, responsible for 1.5 million documented deaths in 2016. The increase in reported cases of M. tuberculosis resistance to the main drugs show the need for the development of new and efficient drugs for better TB control. Based on these facts, this work aimed to use combined in silico techniques for the discovery of potential inhibitors to β-ketoacyl-ACP synthase (MtKasA). Initially compounds from natural sources present in the ZINC database were selected, then filters were sequentially applied by virtual screening, initially with pharmacophoric modeling, and later the selected compounds (based on QFIT scores) were submitted to the DOCK 6.5 program. After recategorization of the variables (QFIT score and GRID score), compounds ZINC35465970 and ZINC31170017 were selected. These compounds showed great hydrophobic contributions and for each established system 100 ns of molecular dynamics simulations were performed and the binding free energy was calculated. ZINC35465970 demonstrated a greater capacity for the KasA enzyme inhibition, with a ΔGbind = -30.90 kcal/mol and ZINC31170017 presented a ΔGbind = -27.49 kcal/mol. These data can be used in other studies that aim at the inhibition of the same biological targets through drugs with a dual action.Entities:
Keywords: molecular docking; pharmacophore model; tuberculosis; virtual screening; β-ketoacyl-ACP synthase
Year: 2019 PMID: 30871010 PMCID: PMC6469180 DOI: 10.3390/ph12010036
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 12D and 3D structures of thiolactomycin (TLM).
Parameters of GALAHAD™ for models from MtKasA inhibitors. The pharmacophore model that presented an energy penalty is indicated by the red color.
| Models | Strain Energy (kcal/mol) | Hbond | Mol-qry |
|---|---|---|---|
| 2 | 7.53 | 650.30 | 112.40 |
| 8 | 7.58 | 613.30 | 114.60 |
| 1 | 8.02 | 619.30 | 127.70 |
| 5 | 9.05 | 497.20 | 122.60 |
| 10 | 9.54 | 478.10 | 125.10 |
| 4 | 10.52 | 520.90 | 128.40 |
| 7 | 45.88 | 504.00 | 126.20 |
| 9 | 67.80 | 550.70 | 132.00 |
| 6 | 69.55 | 482.60 | 136.70 |
|
|
|
|
|
Figure 2Representation of the best pharmacophore model for KasA inihibitors. Pink: Hbond donor; green: Hbond acceptors; cyan: hydrophobic centers. The size of the spheres represents the tolerance. The distances are shown in angstroms (Å).
The five molecules with the best QFIT value.
| Molecule | Structure | QFIT |
|---|---|---|
| ZINC35465970 |
| 66.76 |
| ZINC15959689 |
| 62.97 |
| ZINC16032930 |
| 62.07 |
| ZINC31161132 |
| 59.99 |
| ZINC72320274 |
| 59.86 |
Figure 3Result of the redocking. Crystallographic ligand in cyan and the best docking pose in orange.
Figure 4ROC curves for evaluation of Grid-Hawkins GB/SA and Grid Score.
Figure 5Enrichment factor (EF) for scoring functions used in MtKasA in 1, 5, 10 and 25% of the database.
Figure 6Distribution of compounds according to their affinity energy against MtKasA.
Consensus ranking of variables: relationship between the result of QFIT and Grid + Hawkins GB/SA for MtbKasA.
| MOLECULE | CONSENSUS |
|---|---|
| ZINC35465970 | 122.10 |
| ZINC31170017 | 108.57 |
| ZINC12659549 | 108.52 |
| ZINC08453820 | 107.44 |
| ZINC15959689 | 107.28 |
Figure 7Interactions of compounds against the active site of Mycobacterium tuberculosis KasA, In (A) ZINC35465970 and (B) ZINC31170017.
Figure 8Evaluation of RMSD plots during MD simulations. The KasA protein backbone has been represented in black, while the ligands graphs have been represented in different colors. (a) RMSDs of the KasA- ZINC35465970 system and (b) RMSDs of the KasA-ZINC31170017 system.
Figure 9Protein backbone RMSF plots.
Figure 10Regions of protein that showed greater residue fluctuations.
Hydrogen bonds formed in complexes.
| Acceptor | Hydrogen Donor | Donor | Occupancy (%) a | Average Distance (Å) |
|---|---|---|---|---|
|
| ||||
| ZINC35465970_416@O25 | GLN_170@HE22 | GLN_170@NE2 | 30.46 | 3.17 |
| ZINC35465970_416@O25 | HIS_344@HE2 | HIS_344@NE2 | 28.75 | 3.03 |
| ZINC35465970_416@O24 | LYS_339@HZ3 | LYS_339@NZ | 21.69 | 2.89 |
| ZINC35465970_416@O24 | LYS_339@HZ1 | LYS_339@NZ | 21.19 | 2.89 |
| ZINC35465970_416@O24 | LYS_339@HZ2 | LYS_339@NZ | 20.01 | 2.90 |
|
| ||||
| MET_212@O | ZINC31170017_416@H62 | ZINC31170017_416@O37 | 71.27 | 2.81 |
| ARG_233@O | ZINC31170017_416@H56 | ZINC31170017_416@O22 | 49.69 | 3.01 |
Occupancy is defined as the percentage of time that hydrogen bonding existed during the 100 ns simulation time.
Energy contributions to the free energy binding KasA-compounds.
| Compound | ΔEvdW | ΔEele | ΔGGB | ΔGNP | ΔGbind |
|---|---|---|---|---|---|
| ZINC35465970 | −45.21 | −11.93 | 32.31 | −6.06 | −30.90 |
| ZINC31170017 | −35.86 | −11.48 | 25.04 | −5.18 | −27.49 |
KasA inhibitors selected for construction and evaluation of pharmacophore models.
| Molecule | Structure | Ki (µM) |
|---|---|---|
| 1 |
| 0.46 |
| 2 |
| 0.90 |
| 3 |
| 1.90 |
| 4 |
| 7.10 |
| 5 |
| 16.00 |
| 6 |
| 34.00 |